Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/25439
Title: Experimental and Clinical Treatment of Chagas Disease: A Review
Authors: Sales Junior, Policarpo Ademar
Molina, Israel
Murta, Silvane Maria Fonseca
Sanchez-Montalva, Adrian
Salvador, Fernando
Oliveira, Rodrigo Correa de
Carneiro, Claudia Martins
Affilliation: Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil
Universitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain/Universidade Federal de Ouro Preto. Nucleo de Pesquisas em Ciencias Biologicas. Laboratorio de Imunopatologia. Ouro Preto, MG, Brazil
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil
Universitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain
Universitat Autonoma de Barcelona. Vall d’Hebron University Hospital. Infectious Diseases Department. PROSICS Barcelona, Barcelona, Spain
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil/Universidade Federal de Ouro Preto. Nucleo de Pesquisas em Ciencias Biologicas. Laboratorio de Imunopatologia. Ouro Preto, MG, Brazil
Universidade Federal de Ouro Preto. Nucleo de Pesquisas em Ciencias Biologicas. Laboratorio de Imunopatologia. Ouro Preto, MG, Brazil
Abstract: Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed.Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD.
Keywords: Chagas disease
Trypanosoma cruzi
keywords: Trypanosoma cruzi
Doença de Chagas
Issue Date: 2017
Publisher: American Society of Tropical Medicine and Hygiene
Citation: SALES JUNIOR, Policarpo Ademar et al. Experimental and Clinical Treatment of Chagas Disease: A Review. Am J Trop Med Hyg., v. 97, n. 5, p. 1289-1303, 2017
DOI: 10.4269/ajtmh.16-0761
ISSN: 0002-9637
Copyright: restricted access
Appears in Collections:MG - IRR - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Experimental and Clinical Treatment of Chagas Disease.pdf7.29 MBAdobe PDF    Request a copy


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.